Literature DB >> 26991475

Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.

Robert Brownell1, Naftali Kaminski2, Prescott G Woodruff1, Williamson Z Bradford3, Luca Richeldi4, Fernando J Martinez5, Harold R Collard1.   

Abstract

Precision medicine is defined by the National Institute of Health's Precision Medicine Initiative Working Group as an approach to disease treatment that takes into account individual variability in genes, environment, and lifestyle. There has been increased interest in applying the concept of precision medicine to idiopathic pulmonary fibrosis, in particular to search for genetic and molecular biomarker-based profiles (so called endotypes) that identify mechanistically distinct disease subgroups. The relevance of precision medicine to idiopathic pulmonary fibrosis is yet to be established, but we believe that it holds great promise to provide targeted and highly effective therapies to patients. In this manuscript, we describe the field's nascent efforts in genetic/molecular endotype identification and how environmental and behavioral subgroups may also be relevant to disease management.

Entities:  

Keywords:  biological markers; endotypes; idiopathic pulmonary fibrosis; precision medicine; stratified medicine

Mesh:

Year:  2016        PMID: 26991475      PMCID: PMC5440061          DOI: 10.1164/rccm.201601-0169CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  72 in total

1.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

2.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

3.  Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Jay H Ryu; Brett M Elicker; Carmen P Lydell; Kirk D Jones; Paul J Wolters; Talmadge E King; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

4.  Targeted therapy for lung cancer: present and future.

Authors:  Charu Aggarwal
Journal:  Ann Palliat Med       Date:  2014-07

5.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

6.  Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.

Authors:  K E Greene; T E King; Y Kuroki; B Bucher-Bartelson; G W Hunninghake; L S Newman; H Nagae; R J Mason
Journal:  Eur Respir J       Date:  2002-03       Impact factor: 16.671

Review 7.  From phenotypes to endotypes to asthma treatment.

Authors:  Ioana O Agache
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-06

8.  MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

9.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139

10.  Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts.

Authors:  S K Huang; A M Scruggs; J Donaghy; J C Horowitz; Z Zaslona; S Przybranowski; E S White; M Peters-Golden
Journal:  Cell Death Dis       Date:  2013-05-02       Impact factor: 8.469

View more
  17 in total

1.  Update in Interstitial Lung Disease 2016.

Authors:  Athol U Wells; Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

2.  An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.

Authors:  Arnold S Kristof; Basil J Petrof; Qutayba Hamid; Martin Kolb; Jennifer S Landry; Alex MacKenzie; Francis X McCormack; Inga J Murawski; Joel Moss; Frank Rauch; Ivan O Rosas; Adam J Shapiro; Benjamin M Smith; David Y Thomas; Bruce C Trapnell; Lisa R Young; Maimoona A Zariwala
Journal:  Ann Am Thorac Soc       Date:  2017-08

3.  Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis?

Authors:  Victor J Thannickal; Veena B Antony
Journal:  Expert Rev Respir Med       Date:  2018-04-19       Impact factor: 3.772

Review 4.  Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).

Authors:  Shigeki Saito; Ala Alkhatib; Jay K Kolls; Yasuhiro Kondoh; Joseph A Lasky
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 5.  Mechanisms for the Resolution of Organ Fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Physiology (Bethesda)       Date:  2019-01-01

6.  Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds.

Authors:  Kevin K Kim; Thomas H Sisson; Jeffrey C Horowitz
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

Review 7.  The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Authors:  Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi
Journal:  Lancet Respir Med       Date:  2016-12-06       Impact factor: 30.700

Review 8.  Precision medicine in idiopathic pulmonary fibrosis.

Authors:  T M Maher
Journal:  QJM       Date:  2016-08-10

9.  Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.

Authors:  Eleanor Valenzi; Haopu Yang; John C Sembrat; Libing Yang; Spencer Winters; Rachel Nettles; Daniel J Kass; Shulin Qin; Xiaohong Wang; Michael M Myerburg; Barbara Methé; Adam Fitch; Jonathan K Alder; Panayiotis V Benos; Bryan J McVerry; Mauricio Rojas; Alison Morris; Georgios D Kitsios
Journal:  Thorax       Date:  2020-12-02       Impact factor: 9.139

10.  Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation.

Authors:  Huachun Cui; Na Xie; Sami Banerjee; Jing Ge; Dingyuan Jiang; Tapan Dey; Qiana L Matthews; Rui-Ming Liu; Gang Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2021-01       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.